Search

• GSK’s ECLIPSE study shows association between improving health status and reduced morbidity and mortality in patients with COPD

  Media

  keeping stable health status in patients with COPD significantly reduces the likelihood of exacerbation, hospital admission and dying.

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-eclipse-study-shows-association-between-improving-health-status-and-reduced-morbidity-and-mortality-in-patients-with-copd/

  First published: 18 May 2015

• GSK and the Francis Crick Institute join forces in collaboration to forge new scientific discoveries

  Media

  The Francis Crick Institute and GSK to partner on an innovation collaboration exploring new avenues of medical research and drug discovery

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-the-francis-crick-institute-join-forces-in-collaboration-to-forge-new-scientific-discoveries/

  First published: 14 July 2015

• GSK receives positive CHMP opinion in Europe for novel anti-IL5 biological Nucala (mepolizumab) for the treatment of patients with severe refractory eosinophilic asthma

  Media

  GSK today announced that the CHMP of EMA issued a positive opinion recommending marketing authorisation for mepolizumab

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-in-europe-for-novel-anti-il5-biological-nucala-mepolizumab-for-the-treatment-of-patients-with-severe-refractory-eosinophilic-asthma/

  First published: 24 September 2015

• GSK and MMV announce start of phase III programme of tafenoquine for Plasmodium vivax malaria

  Media

  GSK and Medicines for Malaria Venture (MMV) today announced the start of a phase III global programme.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-mmv-announce-start-of-phase-iii-programme-of-tafenoquine-for-plasmodium-vivax-malaria/

  First published: 28 April 2014

• GSK and Save the Children offer $1 million award for healthcare innovations in developing countries that reduce child deaths

  Media

  GSK and Save the Children today announced the launch of their second annual $1 million Healthcare Innovation Award.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-offer-1-million-award-for-healthcare-innovations-in-developing-countries-that-reduce-child-deaths/

  First published: 30 June 2014

• GSK announces EU regulatory submission for malaria vaccine candidate RTS,S

  Media

  GSK announced today that it has submitted a regulatory application to the EMA for its malaria vaccine candidate, RTS,S.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-for-malaria-vaccine-candidate-rts-s/

  First published: 24 July 2014

• GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes

  Media

  GSK announced the start of a Phase III study to evaluate effects of eltrombopag with azacitidine versus placebo in patients with MDS.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-the-start-of-a-phase-iii-study-with-eltrombopag-in-patients-with-myelodysplastic-syndromes/

  First published: 25 June 2014

• GSK presents data from Phase III STABILITY study of darapladib in patients with chronic coronary heart disease

  Media

  GSK presented data from the pivotal Phase III STABILITY study of darapladib at the American College of Cardiology 63rd Annual Session

  https://www.gsk.com/en-gb/media/press-releases/gsk-presents-data-from-phase-iii-stability-study-of-darapladib-in-patients-with-chronic-coronary-heart-disease/

  First published: 30 March 2014

• GSK receives EU marketing authorisation for Mekinist™ (trametinib) for patients with unresectable or metastatic melanoma with a BRAF V600 mutation

  Media

  GSK announced, the EC has granted marketing authorisation for trametinib as treatment of patients with unresectable/metastatic melanoma

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-eu-marketing-authorisation-for-mekinist-trametinib-for-patients-with-unresectable-or-metastatic-melanoma-with-a-braf-v600-mutation/

  First published: 04 July 2014

• GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the USA for the treatment of asthma

  Media

  GSK announced that the FDA has approved Arnuity™ Ellipta® for treatment of asthma in patients aged 12 years and older.

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-approval-for-arnuity-ellipta-fluticasone-furoate-in-the-usa-for-the-treatment-of-asthma/

  First published: 20 August 2014